Bristol Enterprise Value vs Invested Capital Analysis

BMY Stock

USD 48.99 0.15 0.31%

Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Enterprise Value and its Invested Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Enterprise Value vs Invested Capital

Enterprise Value vs Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Enterprise Value account and Invested Capital. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Bristol Myers' Enterprise Value and Invested Capital is 0.48. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Invested Capital in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Enterprise Value and Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Bristol Myers Squibb are associated (or correlated) with its Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Invested Capital has no effect on the direction of Enterprise Value i.e., Bristol Myers' Enterprise Value and Invested Capital go up and down completely randomly.

Correlation Coefficient

0.48

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Enterprise Value

Enterprise Value (or EV) is usually referred to as Bristol Myers theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Bristol Myers Squibb debt, but would also pocket its cash. Enterprise Value is more accurate representation of Bristol Myers value than its market capitalization because it takes into account all of Bristol Myers Squibb existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to Bristol Myers Squibb. There are two different methods for calculating Bristol Myers Squibb invested capital: operating approach and financing approach. Understanding Bristol Myers invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

At this time, Bristol Myers' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	36.4B	36.0B	34.3B	36.0B
Total Revenue	46.4B	46.2B	45.0B	47.3B

Gross Profit Total Revenue

Bristol Myers fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity
Total Assets		0.98	0.81	0.93	0.89	0.78	0.98	-0.07	0.9	0.99	0.52	0.83	0.76	0.97	0.45	0.99	0.82	-0.16	0.88	0.99	0.7	0.94	0.85	0.96	0.6	0.88
Short Long Term Debt Total	0.98		0.78	0.92	0.84	0.79	1.0	-0.16	0.94	0.97	0.38	0.88	0.82	0.98	0.52	0.99	0.76	-0.24	0.89	0.99	0.76	0.95	0.89	0.95	0.57	0.91
Other Current Liab	0.81	0.78		0.95	0.55	0.69	0.81	-0.1	0.63	0.77	0.64	0.55	0.77	0.81	0.39	0.76	0.52	0.1	0.6	0.83	0.77	0.87	0.67	0.65	0.62	0.73
Total Current Liabilities	0.93	0.92	0.95		0.7	0.8	0.93	-0.07	0.81	0.89	0.52	0.75	0.88	0.95	0.41	0.9	0.66	-0.04	0.73	0.94	0.87	0.97	0.84	0.8	0.66	0.85
Total Stockholder Equity	0.89	0.84	0.55	0.7		0.75	0.84	0.13	0.79	0.91	0.41	0.73	0.5	0.82	0.44	0.88	0.9	-0.14	0.82	0.85	0.43	0.76	0.73	0.93	0.62	0.81
Property Plant And Equipment Net	0.78	0.79	0.69	0.8	0.75		0.79	0.28	0.73	0.76	0.19	0.7	0.77	0.84	0.41	0.78	0.64	-0.13	0.53	0.8	0.75	0.79	0.78	0.7	0.85	0.85
Net Debt	0.98	1.0	0.81	0.93	0.84	0.79		-0.17	0.9	0.98	0.42	0.83	0.82	0.98	0.52	0.99	0.77	-0.21	0.89	0.99	0.76	0.93	0.89	0.95	0.56	0.91
Retained Earnings	-0.07	-0.16	-0.1	-0.07	0.13	0.28	-0.17		-0.12	-0.07	-0.11	-0.07	-0.11	-0.03	-0.62	-0.12	0.17	0.35	-0.45	-0.11	-0.06	-0.05	-0.16	-0.13	0.44	-0.14
Cash	0.9	0.94	0.63	0.81	0.79	0.73	0.9	-0.12		0.87	0.21	0.98	0.78	0.9	0.48	0.92	0.66	-0.32	0.83	0.91	0.69	0.91	0.85	0.87	0.57	0.84
Non Current Assets Total	0.99	0.97	0.77	0.89	0.91	0.76	0.98	-0.07	0.87		0.53	0.8	0.71	0.95	0.46	0.99	0.84	-0.19	0.89	0.98	0.65	0.91	0.83	0.98	0.57	0.86
Non Currrent Assets Other	0.52	0.38	0.64	0.52	0.41	0.19	0.42	-0.11	0.21	0.53		0.12	0.16	0.38	0.18	0.45	0.49	0.12	0.44	0.48	0.18	0.45	0.18	0.45	0.21	0.35
Cash And Short Term Investments	0.83	0.88	0.55	0.75	0.73	0.7	0.83	-0.07	0.98	0.8	0.12		0.76	0.84	0.41	0.85	0.6	-0.37	0.74	0.84	0.67	0.87	0.8	0.8	0.58	0.78
Net Receivables	0.76	0.82	0.77	0.88	0.5	0.77	0.82	-0.11	0.78	0.71	0.16	0.76		0.88	0.35	0.76	0.48	-0.29	0.58	0.8	0.97	0.86	0.87	0.62	0.53	0.8
Good Will	0.97	0.98	0.81	0.95	0.82	0.84	0.98	-0.03	0.9	0.95	0.38	0.84	0.88		0.4	0.97	0.78	-0.19	0.81	0.98	0.83	0.95	0.9	0.9	0.63	0.89
Common Stock Shares Outstanding	0.45	0.52	0.39	0.41	0.44	0.41	0.52	-0.62	0.48	0.46	0.18	0.41	0.35	0.4		0.5	0.2	-0.34	0.69	0.48	0.29	0.4	0.52	0.5	0.27	0.64
Non Current Liabilities Total	0.99	0.99	0.76	0.9	0.88	0.78	0.99	-0.12	0.92	0.99	0.45	0.85	0.76	0.97	0.5		0.8	-0.22	0.9	0.99	0.69	0.93	0.86	0.97	0.58	0.88
Inventory	0.82	0.76	0.52	0.66	0.9	0.64	0.77	0.17	0.66	0.84	0.49	0.6	0.48	0.78	0.2	0.8		-0.07	0.72	0.78	0.45	0.69	0.65	0.86	0.52	0.75
Other Current Assets	-0.16	-0.24	0.1	-0.04	-0.14	-0.13	-0.21	0.35	-0.32	-0.19	0.12	-0.37	-0.29	-0.19	-0.34	-0.22	-0.07		-0.33	-0.18	-0.19	-0.07	-0.32	-0.24	0.15	-0.26
Other Stockholder Equity	0.88	0.89	0.6	0.73	0.82	0.53	0.89	-0.45	0.83	0.89	0.44	0.74	0.58	0.81	0.69	0.9	0.72	-0.33		0.87	0.49	0.77	0.78	0.94	0.3	0.81
Total Liab	0.99	0.99	0.83	0.94	0.85	0.8	0.99	-0.11	0.91	0.98	0.48	0.84	0.8	0.98	0.48	0.99	0.78	-0.18	0.87		0.75	0.96	0.87	0.95	0.61	0.89
Property Plant And Equipment Gross	0.7	0.76	0.77	0.87	0.43	0.75	0.76	-0.06	0.69	0.65	0.18	0.67	0.97	0.83	0.29	0.69	0.45	-0.19	0.49	0.75		0.82	0.83	0.55	0.56	0.75
Total Current Assets	0.94	0.95	0.87	0.97	0.76	0.79	0.93	-0.05	0.91	0.91	0.45	0.87	0.86	0.95	0.4	0.93	0.69	-0.07	0.77	0.96	0.82		0.85	0.84	0.68	0.86
Short Term Debt	0.85	0.89	0.67	0.84	0.73	0.78	0.89	-0.16	0.85	0.83	0.18	0.8	0.87	0.9	0.52	0.86	0.65	-0.32	0.78	0.87	0.83	0.85		0.82	0.53	0.84
Intangible Assets	0.96	0.95	0.65	0.8	0.93	0.7	0.95	-0.13	0.87	0.98	0.45	0.8	0.62	0.9	0.5	0.97	0.86	-0.24	0.94	0.95	0.55	0.84	0.82		0.5	0.83
Accounts Payable	0.6	0.57	0.62	0.66	0.62	0.85	0.56	0.44	0.57	0.57	0.21	0.58	0.53	0.63	0.27	0.58	0.52	0.15	0.3	0.61	0.56	0.68	0.53	0.5		0.64
Common Stock Total Equity	0.88	0.91	0.73	0.85	0.81	0.85	0.91	-0.14	0.84	0.86	0.35	0.78	0.8	0.89	0.64	0.88	0.75	-0.26	0.81	0.89	0.75	0.86	0.84	0.83	0.64

Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Short Long Term Debt Total	47.5B	51.7B	45.6B	40.7B	41.5B	43.5B
Other Current Liab	7.9B	10.2B	10.1B	13.1B	11.5B	12.1B
Total Current Liabilities	18.3B	19.1B	21.9B	21.9B	22.3B	23.4B
Total Stockholder Equity	51.6B	37.8B	35.9B	31.1B	29.4B	15.0B
Property Plant And Equipment Net	6.3B	6.7B	7.0B	7.5B	8.0B	5.2B
Net Debt	35.2B	37.1B	31.6B	31.6B	30B	31.5B
Retained Earnings	34.5B	21.3B	23.8B	25.5B	28.8B	22.0B
Cash	12.3B	14.5B	14.0B	9.1B	11.5B	12.0B
Non Current Assets Total	100.6B	88.3B	76.1B	69.5B	63.4B	66.6B
Non Currrent Assets Other	6.6B	2.1B	1.7B	1.0B	1.9B	2.0B
Cash And Short Term Investments	12.3B	14.5B	14.0B	9.1B	12.3B	12.9B
Net Receivables	7.7B	8.5B	12.5B	13.9B	15.3B	16.0B
Good Will	22.5B	20.5B	20.5B	21.1B	21.2B	22.2B
Common Stock Shares Outstanding	1.7B	2.3B	2.2B	2.1B	2.1B	1.6B
Liabilities And Stockholders Equity	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Non Current Liabilities Total	59.9B	61.5B	51.4B	43.8B	43.4B	45.6B
Inventory	4.3B	2.1B	2.1B	2.3B	2.7B	1.9B
Other Current Assets	2.0B	1.4B	1.3B	1.6B	1.5B	1.8B
Other Stockholder Equity	18.4B	18.1B	13.1B	6.5B	1.9B	2.0B
Total Liab	78.2B	80.6B	73.3B	65.7B	65.7B	69.0B
Property Plant And Equipment Gross	6.3B	5.9B	11.0B	11.6B	12.8B	13.5B
Total Current Assets	29.4B	30.2B	33.3B	27.3B	31.8B	33.4B
Accumulated Other Comprehensive Income	(1.5B)	(1.8B)	(1.3B)	(1.3B)	(1.5B)	(1.6B)
Short Term Debt	3.5B	2.5B	5.1B	4.4B	3.3B	3.4B
Intangible Assets	64.0B	53.2B	42.8B	36.4B	27.5B	28.9B
Accounts Payable	2.4B	2.7B	2.9B	3.0B	3.3B	1.9B
Short Term Investments	3.0B	1.3B	3.2B	130M	816M	775.2M
Other Liab	15.9B	12.3B	11.0B	7.4B	8.5B	4.9B
Other Assets	4.8B	7.3B	3.3B	2.9B	3.3B	3.3B
Long Term Debt	43.4B	48.3B	39.6B	35.1B	36.7B	38.5B
Treasury Stock	(25.4B)	(26.2B)	(31.3B)	(38.6B)	(43.8B)	(41.6B)
Property Plant Equipment	6.3B	5.9B	6.0B	6.3B	7.2B	5.8B
Current Deferred Revenue	4.5B	3.6B	3.7B	1.3B	4.2B	4.4B
Net Tangible Assets	(34.9B)	(36.0B)	(28.2B)	(25.9B)	(23.4B)	(22.2B)
Noncontrolling Interest In Consolidated Entity	96M	100M	60M	57M	55M	74.7M

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

0.79

Agilent Technologies Earnings Call This Week

Pair Corr

Moving against Bristol Stock

0.47

VALN

Valneva SE ADR Financial Report 2nd of May 2024

Pair Corr

The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.

The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:

How To Invest In Bristol

Details

Is Bristol Stock a good investment?

Details

What is Bristol Myers' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Commodity Directory Find actively traded commodities issued by global exchanges
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals

Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.09)

Dividend Share

2.31

Earnings Share

3.86

Revenue Per Share

21.753

Quarterly Revenue Growth

0.006

The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Enterprise Value vs Invested Capital Analysis

Enterprise Value vs Invested Capital

Enterprise Value vs Invested Capital Correlation Analysis

Correlation Coefficient

Enterprise Value

Invested Capital

Bristol Myers fundamental ratios Correlations

Bristol Myers Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bristol Myers fundamental ratios Accounts

Pair Trading with Bristol Myers

Moving together with Bristol Stock

Moving against Bristol Stock

Complementary Tools for Bristol Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.62	Retained Earnings
Other Stockholder Equity	- 0.45	Retained Earnings
Other Current Assets	- 0.37	Cash And Short Term Investments
Other Current Assets	- 0.34	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.33	Other Current Assets
Short Term Debt	- 0.32	Other Current Assets